previously tested as a COVID-19 vaccine candidate in Phase II and III clinical trials in South Korea and the Philippines, demonstrates significant potential for adaptability. Developed in partnership with UB spinoff POP Biotechnologies and South Korean company EuBiologics, the CoPoP platform’s
April 22, 2025 at 4:09 PM
previously tested as a COVID-19 vaccine candidate in Phase II and III clinical trials in South Korea and the Philippines, demonstrates significant potential for adaptability. Developed in partnership with UB spinoff POP Biotechnologies and South Korean company EuBiologics, the CoPoP platform’s
We are pleased to announce the initiation of the new EuNmCV5 Meningitis Vaccine Study, in collaboration with our partners, #EuBiologics & @pathmalaria.bsky.social.
This critical study aims to ensure the safety & effectiveness of the vaccine in preventing meningitis in children.
#GlobalHealth
This critical study aims to ensure the safety & effectiveness of the vaccine in preventing meningitis in children.
#GlobalHealth
January 22, 2025 at 1:36 PM
We are pleased to announce the initiation of the new EuNmCV5 Meningitis Vaccine Study, in collaboration with our partners, #EuBiologics & @pathmalaria.bsky.social.
This critical study aims to ensure the safety & effectiveness of the vaccine in preventing meningitis in children.
#GlobalHealth
This critical study aims to ensure the safety & effectiveness of the vaccine in preventing meningitis in children.
#GlobalHealth
#Typhoid is a serious public health threat in many parts of the world. We can prevent it with vaccines—but to ensure access, we need more of them.
That's why PATH supported a study of #EuBiologics’ new typhoid vaccine. Results are promising: https://bit.ly/4r8aBKb
#VaccinesWork #TakeOnTyphoid
That's why PATH supported a study of #EuBiologics’ new typhoid vaccine. Results are promising: https://bit.ly/4r8aBKb
#VaccinesWork #TakeOnTyphoid
More vaccines, more protection: Promising results for new typhoid conjugate vaccine
Phase 3 results from a trial of a new typhoid conjugate vaccine show positive results, offering the potential for an additional product to increase access.
www.path.org
November 17, 2025 at 2:27 PM
#Typhoid is a serious public health threat in many parts of the world. We can prevent it with vaccines—but to ensure access, we need more of them.
That's why PATH supported a study of #EuBiologics’ new typhoid vaccine. Results are promising: https://bit.ly/4r8aBKb
#VaccinesWork #TakeOnTyphoid
That's why PATH supported a study of #EuBiologics’ new typhoid vaccine. Results are promising: https://bit.ly/4r8aBKb
#VaccinesWork #TakeOnTyphoid
EuBiologics Targets Global Typhoid Vaccine Market After WHO Approval
EuBiologics Targets Global Typhoid Vaccine Market After WHO Approval
Korean vaccine manufacturer EuBiologics secured World Health Organization prequalification for its typhoid conjugate vaccine, EuTYPH-C, in August with backing from the Research Investment for Global Health Technology Foundation. The company aims to …
nexa.news
September 27, 2026 at 6:40 AM
EuBiologics Targets Global Typhoid Vaccine Market After WHO Approval
📢 A new #typhoid vaccine is now one step closer to reaching more children.
EuBiologics’ typhoid conjugate vaccine has been @who.int prequalified, adding another vaccine option for countries working to prevent #typhoid.
📖Read more: https://bit.ly/45SxFTG
EuBiologics’ typhoid conjugate vaccine has been @who.int prequalified, adding another vaccine option for countries working to prevent #typhoid.
📖Read more: https://bit.ly/45SxFTG
August 31, 2026 at 3:50 PM
📢 A new #typhoid vaccine is now one step closer to reaching more children.
EuBiologics’ typhoid conjugate vaccine has been @who.int prequalified, adding another vaccine option for countries working to prevent #typhoid.
📖Read more: https://bit.ly/45SxFTG
EuBiologics’ typhoid conjugate vaccine has been @who.int prequalified, adding another vaccine option for countries working to prevent #typhoid.
📖Read more: https://bit.ly/45SxFTG
"GC Biopharma presents mRNA vaccines strategy at Global Vaccine Forum"
#Health #Healthcare #ElderCare #MedSky
#Health #Healthcare #ElderCare #MedSky
GC Biopharma presents mRNA vaccines strategy at Global Vaccine Forum
GC Biopharma presented its mRNA vaccine development strategy at the Global Vaccine Forum in Seoul on Thursday.The International Vaccine Institute (IVI) and EuBiologics jointly organized the forum, which had the theme “Present and future of mRNA and other vaccine platform technologies.”GC Biopharma b
www.koreabiomed.com
June 20, 2025 at 5:23 AM
"GC Biopharma presents mRNA vaccines strategy at Global Vaccine Forum"
#Health #Healthcare #ElderCare #MedSky
#Health #Healthcare #ElderCare #MedSky
🌍 #MemberMonday: 𝗣𝗔𝗧𝗛
Typhoid is a major public health threat, but it’s preventable with vaccines. PATH supported a study of EuBiologics’ new typhoid conjugate vaccine—showing promising results for expanding protection.
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗵𝗲𝗿𝗲: lnkd.in/e-Xmyt73
Typhoid is a major public health threat, but it’s preventable with vaccines. PATH supported a study of EuBiologics’ new typhoid conjugate vaccine—showing promising results for expanding protection.
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗵𝗲𝗿𝗲: lnkd.in/e-Xmyt73
November 17, 2025 at 3:28 PM
🌍 #MemberMonday: 𝗣𝗔𝗧𝗛
Typhoid is a major public health threat, but it’s preventable with vaccines. PATH supported a study of EuBiologics’ new typhoid conjugate vaccine—showing promising results for expanding protection.
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗵𝗲𝗿𝗲: lnkd.in/e-Xmyt73
Typhoid is a major public health threat, but it’s preventable with vaccines. PATH supported a study of EuBiologics’ new typhoid conjugate vaccine—showing promising results for expanding protection.
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗵𝗲𝗿𝗲: lnkd.in/e-Xmyt73
Il s'agit de SK Bioscience, EuBiologics, Cellid, Genexine et Gene One Life Science. Le gouvernement investira environ 68,7 milliards de wons cette année pour soutenir le coût des essais cliniques et, si nécessaire, envisagera de revoir des plans de soutien supplémentaires.
January 8, 2025 at 9:19 AM
Il s'agit de SK Bioscience, EuBiologics, Cellid, Genexine et Gene One Life Science. Le gouvernement investira environ 68,7 milliards de wons cette année pour soutenir le coût des essais cliniques et, si nécessaire, envisagera de revoir des plans de soutien supplémentaires.
@isv-news.bsky.social #ISV2025
Sin-Hee Jun, EuBiologics Inc., Korea: vaccines and biologics technology from Korea. Very interesting adjuvant technology?
Sin-Hee Jun, EuBiologics Inc., Korea: vaccines and biologics technology from Korea. Very interesting adjuvant technology?
October 30, 2025 at 2:21 PM
@isv-news.bsky.social #ISV2025
Sin-Hee Jun, EuBiologics Inc., Korea: vaccines and biologics technology from Korea. Very interesting adjuvant technology?
Sin-Hee Jun, EuBiologics Inc., Korea: vaccines and biologics technology from Korea. Very interesting adjuvant technology?
🎥 Fondation Mérieux posted a video
GTFCC Eubiologics
www.youtube.com
March 21, 2025 at 7:12 AM
🎥 Fondation Mérieux posted a video
#JustPublished in @lancetgh.bsky.social: results from a Phase 3 clinical trial of #EuBiologics’ typhoid conjugate vaccine. The vaccine demonstrates strong safety & immunogenicity—a crucial step toward a sustainable supply of lifesaving typhoid vaccine. https://bit.ly/47HyvVe
#TakeOnTyphoid
#TakeOnTyphoid
EuTYPH-C Inj.® Multi-dose demonstrates strong safety and immunogenicity: Results now available from a Phase 3 study
bit.ly
November 13, 2025 at 2:35 PM
#JustPublished in @lancetgh.bsky.social: results from a Phase 3 clinical trial of #EuBiologics’ typhoid conjugate vaccine. The vaccine demonstrates strong safety & immunogenicity—a crucial step toward a sustainable supply of lifesaving typhoid vaccine. https://bit.ly/47HyvVe
#TakeOnTyphoid
#TakeOnTyphoid
Vaccines have transformed the #meningitis prevention landscape in the last 15 years. But to ensure sustainable access & #DefeatMeningitis by 2030, we need more options. PATH is working with EuBiologics & partners worldwide to advance a new vaccine candidate: bit.ly/3EuFyEW
#WorldImmunizationWeek
#WorldImmunizationWeek
What's next for meningitis prevention? More vaccine options
The meningococcal meningitis prevention landscape has transformed in the last 15 years with the introduction of affordable, effective vaccines to the African meningitis belt. But we need more to ensur...
www.path.org
April 28, 2025 at 1:14 PM
Vaccines have transformed the #meningitis prevention landscape in the last 15 years. But to ensure sustainable access & #DefeatMeningitis by 2030, we need more options. PATH is working with EuBiologics & partners worldwide to advance a new vaccine candidate: bit.ly/3EuFyEW
#WorldImmunizationWeek
#WorldImmunizationWeek